WN 1316

Drug Profile

WN 1316

Alternative Names: WN1316

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neugen Pharma; Wakunaga Pharmaceutical
  • Developer Neugen Pharma
  • Class Acetamides; Cytoprotectives; Imidazoles; Neuroprotectants; Pyridines; Small molecules
  • Mechanism of Action Antioxidants; Astrocyte inhibitors; Glial cell inhibitors; Neuronal apoptosis-inhibitory protein stimulants; NF E2 related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Amyotrophic lateral sclerosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Amyotrophic-lateral-sclerosis(In volunteers) in Japan (PO, Liquid)
  • 05 Mar 2015 Neugen Pharma completes an investigator-sponsored phase I trial in Amyotrophic lateral sclerosis (In volunteers) in Japan (PO) (UMIN000015054)
  • 10 Sep 2014 Phase-I clinical trials in Amyotrophic lateral sclerosis (In volunteers) in Japan (PO) (UMIN000015054)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top